2024
Tumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making
Sobirey R, Matuschewski N, Gross M, Lin M, Kao T, Kasolowsky V, Strazzabosco M, Stein S, Savic L, Gebauer B, Jaffe A, Duncan J, Madoff D, Chapiro J. Tumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making. European Radiology 2024, 1-11. PMID: 39033181, DOI: 10.1007/s00330-024-10955-6.Peer-Reviewed Original ResearchMedian overall survivalTumor response criteriaTumor response assessmentHepatocellular carcinoma patientsHepatocellular carcinomaTumor responseOverall survivalResponse criteriaResponse assessmentNon-respondersPoorer median overall survivalPrediction of tumor responsePredictive valueHepatocellular carcinoma immunotherapyDisease controlPrognostic of survivalClinical baseline parametersLog-rank testKaplan-Meier curvesMultivariate Cox regressionPredicting overall survivalCox regression modelsSurvival benefitStratify patientsMRI pre-
2022
Analysis of Tumor Burden as a Biomarker for Patient Survival with Neuroendocrine Tumor Liver Metastases Undergoing Intra-Arterial Therapies: A Single-Center Retrospective Analysis
Miszczuk M, Chapiro J, Do Minh D, van Breugel JMM, Smolka S, Rexha I, Tegel B, Lin M, Savic LJ, Hong K, Georgiades C, Nezami N. Analysis of Tumor Burden as a Biomarker for Patient Survival with Neuroendocrine Tumor Liver Metastases Undergoing Intra-Arterial Therapies: A Single-Center Retrospective Analysis. CardioVascular And Interventional Radiology 2022, 45: 1494-1502. PMID: 35941241, PMCID: PMC9587516, DOI: 10.1007/s00270-022-03209-9.Peer-Reviewed Original ResearchConceptsNeuroendocrine tumor liver metastasesMedian overall survivalIntra-arterial therapyLow tumor burdenTumor burdenOverall survivalLiver metastasesPrognostic factorsTumor diameterTB groupLonger median overall survivalRetrospective single-center analysisSingle-center retrospective analysisHigh TB groupLow TB groupRespective hazard ratiosHigh tumor burdenSingle-center analysisIndependent prognostic factorStrong prognostic factorDrug-eluting beadsLargest liver lesionPrediction of survivalHazard ratioPatient survivalOptimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI.
Borde T, Nezami N, Laage Gaupp F, Savic LJ, Taddei T, Jaffe A, Strazzabosco M, Lin M, Duran R, Georgiades C, Hong K, Chapiro J. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. Radiology 2022, 304: 228-237. PMID: 35412368, PMCID: PMC9270683, DOI: 10.1148/radiol.212426.Peer-Reviewed Original ResearchConceptsMedian overall survivalAdvanced-stage hepatocellular carcinomaTransarterial chemoembolizationHepatocellular carcinomaBCLC BBCLC COverall survivalTumor burdenBarcelona Clinic Liver Cancer (BCLC) staging systemLiver Cancer staging systemCancer (AJCC) staging systemConventional transarterial chemoembolizationDrug-eluting beadsAllocation of patientsContrast-enhanced MRIBackground PatientsSurvival benefitRetrospective studyStaging systemC tumorsTumor volumePatientsHeterogeneous patientsMonthsChemoembolization
2021
Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial
Letzen BS, Malpani R, Miszczuk M, de Ruiter QMB, Petty CW, Rexha I, Nezami N, Laage-Gaupp F, Lin M, Schlachter TR, Chapiro J. Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial. Clinical Imaging 2021, 78: 194-200. PMID: 34022765, PMCID: PMC8364875, DOI: 10.1016/j.clinimag.2021.05.007.Peer-Reviewed Original ResearchConceptsConventional trans-arterial chemoembolizationMedian overall survivalProspective clinical trialsLipiodol depositionTumor responsePredictive biomarkersClinical trialsModified Response Evaluation CriteriaPost-TACE CTResponse Evaluation CriteriaMetastatic liver cancerKaplan-Meier analysisTrans-arterial chemoembolizationTumor response criteriaLiver tumor responsePrediction of survivalSelective drug targetingArterial embolizationLiver metastasesOverall survivalBland-Altman plotsTransarterial chemoembolizationPortal veinTumor respondersHepatocellular carcinomaThermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma
Chai NX, Chapiro J, Petukhova A, Gross M, Kucukkaya A, Raju R, Zeevi T, Elbanan M, Lin M, Perez-Lozada JC, Schlachter T, Strazzabosco M, Pollak JS, Madoff DC. Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma. Clinical Imaging 2021, 76: 123-129. PMID: 33592550, PMCID: PMC8217099, DOI: 10.1016/j.clinimag.2021.01.043.Peer-Reviewed Original ResearchConceptsOverall survivalTransarterial chemoembolizationHepatocellular carcinomaThermal ablationTA groupEarly-stage hepatocellular carcinomaMedian overall survivalTherapy-naïve patientsKaplan-Meier analysisMaximum tumor diameterStage hepatocellular carcinomaLog-rank testDrug-eluting beadsSmall hepatocellular carcinomaTerms of TTPHIPAA-compliant IRBSignificant differencesLipiodol-TACELocoregional therapyBCLC stageComplication rateTreatment cohortsTumor diameterAFP levelsPatient group
2020
Quantitative volumetric assessment of baseline enhancing tumor volume as an imaging biomarker predicts overall survival in patients with glioblastoma
Auer TA, Della Seta M, Collettini F, Chapiro J, Zschaeck S, Ghadjar P, Badakhshi H, Florange J, Hamm B, Budach V, Kaul D. Quantitative volumetric assessment of baseline enhancing tumor volume as an imaging biomarker predicts overall survival in patients with glioblastoma. Acta Radiologica 2020, 62: 1200-1207. PMID: 32938221, DOI: 10.1177/0284185120953796.Peer-Reviewed Original ResearchConceptsProgression-free survivalOverall survivalTumor volumeGlioblastoma multiformeMagnetic resonance imagingMultivariable analysisCommon malignant primary brain tumorIntracranial progression-free survivalKarnofsky performance status scoreCranial magnetic resonance imagingMalignant primary brain tumorMedian overall survivalPerformance status scoreOS of patientsCox regression modelSignificant prognostic rolePrimary brain tumorsContrast-enhanced MRI sequencesQuantitative volumetric assessmentResection statusPrognostic roleMethyltransferase statusWorse prognosisEntire cohortNon-invasive method
2018
Irinotecan-Eluting 75–150-μm Embolics Lobar Chemoembolization in Patients with Colorectal Cancer Liver Metastases: A Prospective Single-Center Phase I Study
Fereydooni A, Letzen B, Ghani MA, Miszczuk MA, Huber S, Chapiro J, Schlachter T, Geschwind JF, Georgiades C. Irinotecan-Eluting 75–150-μm Embolics Lobar Chemoembolization in Patients with Colorectal Cancer Liver Metastases: A Prospective Single-Center Phase I Study. Journal Of Vascular And Interventional Radiology 2018, 29: 1646-1653.e5. PMID: 30337148, DOI: 10.1016/j.jvir.2018.08.010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsBiomarkers, TumorChemoembolization, TherapeuticColorectal NeoplasmsConnecticutDrug CarriersFeasibility StudiesFemaleHumansIrinotecanLiver NeoplasmsMaleMicrospheresMiddle AgedPalliative CareProspective StudiesTime FactorsTomography, X-Ray ComputedTreatment OutcomeVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth Factor Receptor-2ConceptsVascular endothelial growth factor receptor 1Transarterial chemoembolizationAdverse eventsMetastatic diseaseObjective responseColorectal cancer liver metastasesLiver-dominant metastatic diseaseMetastatic colorectal cancer refractorySingle-center phase IColorectal cancer refractoryLines of chemotherapyMedian overall survivalPrimary end pointCancer liver metastasesResponse Evaluation CriteriaOnly grade 3Drug-eluting embolicsImaging-based criteriaGrowth factor receptor 1Factor receptor 1World Health OrganizationCancer refractoryAbdominal painSystemic chemotherapyLiver metastases
2017
Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model
Do Minh D, Chapiro J, Gorodetski B, Huang Q, Liu C, Smolka S, Savic LJ, Wainstejn D, Lin M, Schlachter T, Gebauer B, Geschwind JF. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model. European Radiology 2017, 27: 4995-5005. PMID: 28677067, PMCID: PMC5675796, DOI: 10.1007/s00330-017-4856-2.Peer-Reviewed Original ResearchConceptsMultivariate Cox proportional hazards modelConventional transarterial chemoembolisationMedian overall survivalPropensity score analysisHepatic progression-free survivalDrug-eluting beads TACEYttrium-90 radioembolisationProgression-free survivalDEB-TACELiver metastasesOverall survivalBeads TACENeuroendocrine tumor liver metastasesWorld Health Organization criteriaCox proportional hazards modelIntra-arterial therapyMethodsThis retrospective analysisResponse Evaluation CriteriaScore analysisSignificant survival benefitLonger overall survivalGastroenteropancreatic neuroendocrine tumorsLog-rank testEntire study populationProportional hazards model
2016
Renal Cell Carcinoma Metastatic to the Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis
Fleckenstein FN, Schernthaner RE, Duran R, Sohn JH, Sahu S, Marshall K, Lin M, Gebauer B, Chapiro J, Salem R, Geschwind JF. Renal Cell Carcinoma Metastatic to the Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis. Translational Oncology 2016, 9: 377-383. PMID: 27641641, PMCID: PMC5021812, DOI: 10.1016/j.tranon.2016.07.005.Peer-Reviewed Original ResearchRenal cell carcinomaOverall survivalIntraarterial therapyMagnetic resonance imagingTumor responseTumor volumeMetastatic renal cell carcinomaRenal cell carcinoma metastaticCox proportional hazards modelEarly response assessmentMedian overall survivalResponse Evaluation CriteriaKaplan-Meier curvesLog-rank testCourse of diseaseProportional hazards modelQuantitative European AssociationOnly significant predictorWorld Health OrganizationRCC metastaticCarcinoma metastaticLiver metastasesCell carcinomaSurrogate markerTreatment responseAdvanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization
Gorodetski B, Chapiro J, Schernthaner R, Duran R, Lin M, Lee H, Lenis D, Stuart EA, Nonyane BA, Pekurovsky V, Tamrazi A, Gebauer B, Schlachter T, Pawlik TM, Geschwind JF. Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. European Radiology 2016, 27: 526-535. PMID: 27277261, PMCID: PMC5470590, DOI: 10.1007/s00330-016-4445-9.Peer-Reviewed Original ResearchConceptsMedian overall survivalPortal venous thrombosisAdvanced-stage hepatocellular carcinomaConventional TACEDEB-TACEHepatocellular carcinomaOverall survivalAdverse eventsBeads TACEDrug-eluting bead transcatheter arterial chemoembolizationConventional trans-arterial chemoembolizationPropensity scoreDrug-eluting beads TACECommon adverse eventsConclusionOur retrospective studyEqual safety profileChild-Pugh classMethodsThis retrospective analysisPortal vein thrombosisPost-embolization syndromeTranscatheter arterial chemoembolizationStage hepatocellular carcinomaTrans-arterial chemoembolizationSub-group analysisArterial chemoembolization
2014
Transarterial chemoembolization in soft-tissue sarcoma metastases to the liver – The use of imaging biomarkers as predictors of patient survival
Chapiro J, Duran R, Lin M, Mungo B, Schlachter T, Schernthaner R, Gorodetski B, Wang Z, Geschwind JF. Transarterial chemoembolization in soft-tissue sarcoma metastases to the liver – The use of imaging biomarkers as predictors of patient survival. European Journal Of Radiology 2014, 84: 424-430. PMID: 25542065, PMCID: PMC4315698, DOI: 10.1016/j.ejrad.2014.11.034.Peer-Reviewed Original ResearchConceptsMetastatic soft tissue sarcomaProgression-free survivalConventional transarterial chemoembolizationSoft tissue sarcomasOverall survivalTumor responseTransarterial chemoembolizationPatient survivalSafety profileCox proportional hazard ratio analysisProportional hazard ratio analysisSoft tissue sarcoma metastasisMedian overall survivalSalvage therapy optionsHazard ratio analysisReliable clinical dataSize-based criteriaEASL guidelinesModified RECISTIntraarterial therapySarcoma metastasisSurvival outcomesGrade IIIKaplan-MeierTherapy optionsUveal Melanoma Metastatic to the Liver: The Role of Quantitative Volumetric Contrast-Enhanced MR Imaging in the Assessment of Early Tumor Response after Transarterial Chemoembolization
Duran R, Chapiro J, Frangakis C, Lin M, Schlachter TR, Schernthaner RE, Wang Z, Savic LJ, Tacher V, Kamel IR, Geschwind JF. Uveal Melanoma Metastatic to the Liver: The Role of Quantitative Volumetric Contrast-Enhanced MR Imaging in the Assessment of Early Tumor Response after Transarterial Chemoembolization. Translational Oncology 2014, 7: 447-455. PMID: 24953419, PMCID: PMC4202794, DOI: 10.1016/j.tranon.2014.05.004.Peer-Reviewed Original ResearchFirst transarterial chemoembolizationEarly tumor responseTransarterial chemoembolizationWorld Health OrganizationOverall survivalTumor responseTarget lesionsTumor volumeTumor enhancementUveal melanomaContrast-enhanced magnetic resonance imagingNon-target lesionsUveal melanoma metastaticMedian overall survivalResponse Evaluation CriteriaKaplan-Meier methodLog-rank testMetastatic uveal melanomaMagnetic resonance imagingMelanoma metastaticSurrogate biomarkerSolid tumorsResonance imagingResponse criteriaLesions